Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals's GHG Emissions Data Preview
In 2024, Hikma Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Hikma Pharmaceuticals has also provided a category-level breakdown for 9 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy/Paste is a PRO feature.  a | Copy/Paste is a PRO feature.  a | 0000000 |
Total Scope 2 | ||||
Market-Based | Copy/Paste is a PRO feature.  a | 0000000 | Copy/Paste is a PRO feature.  a | 0000000 |
Location-Based | Copy/Paste is a PRO feature.  a | 0000000 | Copy/Paste is a PRO feature.  a | 0000000 |
Total Scope 3 | Copy/Paste is a PRO feature.  a | Copy/Paste is a PRO feature.  a | 0000000 | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 0000000 | Copy/Paste is a PRO feature.  a | Copy/Paste is a PRO feature.  a | 0000000 |
a
a
a
a
a
a
a
Verified Sources Behind Hikma Pharmaceuticals’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Hikma Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.
Insights into Hikma Pharmaceuticals's Operational Emissions
In 2024, the total operational greenhouse gas (GHG) emissions of Hikma Pharmaceuticals amounted to 125,705 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Hikma Pharmaceuticals decreased by 1.3%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
Hikma Pharmaceuticals's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Hikma Pharmaceuticals's Scope 1 emissions?
In 2024, the total Scope 1 emissions of Hikma Pharmaceuticals were 38,468 metric tons of CO₂ equivalent (tCO₂e).a
Has Hikma Pharmaceuticals reduced its Scope 1 emissions over time?
Since 2020, Hikma Pharmaceuticals's Scope 1 emissions have decreased by 18.8%, reflecting a declining long-term trend in Scope 1 emissions over time.a
Compared to the previous year (2023), Hikma Pharmaceuticals's Scope 1 emissions decreased by 12.23%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
What are Hikma Pharmaceuticals's Scope 2 emissions?
In 2024, Hikma Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 81,804 tCO₂e using the market-based method and 87,237 tCO₂e using the location-based method.a
Has Hikma Pharmaceuticals reduced its Scope 2 emissions over time?
Since 2020, Hikma Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions (Location-Based) have remained relatively stable, indicating that Hikma Pharmaceuticals's emissions have plateaued with no significant change in its energy consumption footprint.a
Compared to the previous year (2023), Hikma Pharmaceuticals's Scope 2 emissions (Location-Based) have remained relatively stable, indicating that Hikma Pharmaceuticals's emissions have plateaued with no significant change in its energy consumption footprint.a
What methodology does Hikma Pharmaceuticals use for Scope 2 reporting?
In 2024, Hikma Pharmaceuticals reported its Scope 2 emissions using the market-based method and using the location-based method.a
Hikma Pharmaceuticals's Scope 2 Emissions Over Time
- Total Scope 2 Location-Based
- Total Scope 2 Market-Based
Insights into Hikma Pharmaceuticals's Value Chain Emissions
In 2024, Hikma Pharmaceuticals reported 860,710 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of Hikma Pharmaceuticals includes a breakdown across 9 of the 15 Scope 3 categories defined by the GHG Protocol, up from 7 in 2023, reflecting improved emissions accounting practices and greater transparency across the company's value chaina
Hikma Pharmaceuticals's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Hikma Pharmaceuticals's Scope 3 emissions?
In 2024, Hikma Pharmaceuticals reported total Scope 3 emissions of 860,710 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 94.15% of these emissions originated from upstream activities such as purchased goods and capital goods, while 5.85% came from downstream activities like product use, distribution, and end-of-life treatment.a
Compared to the previous year (2023), Hikma Pharmaceuticals's Scope 3 emissions remained relatively stable, indicating that Hikma Pharmaceuticals's emissions have plateaued with no significant change in its value chain footprint.a
What categories of Scope 3 emissions does Hikma Pharmaceuticals disclose?
In 2024, Hikma Pharmaceuticals reported emissions for 9 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This partial disclosure allows for some insight into the company's indirect impacts.
What are the main sources of Hikma Pharmaceuticals's Scope 3 emissions?
In 2024, the largest contributors to Hikma Pharmaceuticals's Scope 3 emissions were:a
- Purchased Goods and Services (Cat. 1): 681,235 tCO₂e (79.15%)
- Capital Goods (Cat. 2): 46,580 tCO₂e (5.41%)
- Use of Sold Products (Cat. 11): 42,089 tCO₂e (4.89%)
Hikma Pharmaceuticals's Scope 3 Emissions by Categories
Insights into Hikma Pharmaceuticals’s GHG Emissions Intensity Compared to Industry Peers
In 2024, Hikma Pharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 38,468 tCO₂e and total revenues of USD 2,307 millions. This translates into an emissions intensity of 16.67 tCO₂e per millions USD.a
Hikma Pharmaceuticals's Scope 1 Emissions Intensity Compared to Peers
How does Hikma Pharmaceuticals's GHG emissions intensity compare to its peers?
In 2024, Hikma Pharmaceuticals reported a Scope 1 emissions intensity of 16.67 tCO₂e per millions USD. Compared to the peer group median of 14.5, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
Where does Hikma Pharmaceuticals rank on GHG emissions intensity within its industry?
In 2024, Hikma Pharmaceuticals ranked 14 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Hikma Pharmaceuticals is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
Insights into Hikma Pharmaceuticals's Total Carbon Footprint
In 2024, Hikma Pharmaceuticals reported a total carbon footprint of 986,415 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 2.29% increase compared to 2023, suggesting a rise in emissions across its operations or value chain.a
The largest contributor to Hikma Pharmaceuticals's total carbon footprint was Scope 3 emissions, accounting for 87.26% of the company's total carbon footprint, followed by Scope 2 emissions at 8.84%.a